| Sep 27 |
Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans?
|
| Sep 18 |
FDA lifts partial clinical hold on Vigil Neuroscience’s Phase I VG-3927 trial
|
| Sep 17 |
Vigil says FDA removed partial hold on Alzheimer’s candidate
|
| Sep 17 |
Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927
|
| Aug 13 |
Vigil Neuroscience GAAP EPS of -$0.52
|
| Aug 13 |
Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update
|
| Aug 1 |
Vigil Neuroscience Highlights Publication on ALSP Genetic Mutation Prevalence in Neurology Genetics
|
| Jul 30 |
Vigil Presents Data on its Small Molecule TREM2 Agonist Program at 2024 Alzheimer's Association International Conference (AAIC)
|
| Jul 24 |
Small Neurodegenerative Disease-Focused Vigil Neuroscience Says Alzheimer's Candidate Shows Significant Impact On Disease Bimarker
|
| Jul 24 |
Vigil Neuroscience reports interim data from its once-daily oral therapy for Alzheimer’s
|
